The capital is intended for the on-going Phase II clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; interim
Avraham Pharmaceuticals Closes an Additional Investment Round of Approximately $6 Million by Yissum, Pontifax and Clal Biotechnology IndustriesMoni Horovitz2022-08-25T08:57:48+00:00